Biologics CDMO Market Expected to Reach $80.05 billion by 2032- BIS Research

The Biologics Contract Development and Manufacturing Organization (CDMO) sector is currently experiencing growth in its life cycle. This growth is marked by a rising acceptance of biologics, an increasing need for outsourced manufacturing services, and a growing investment in expanding CDMO capacity.

The global biologics CDMO market is projected to reach $80.05 billion by 2032 from $19.00 billion in 2022, growing at a CAGR of 15.43% during the forecast period 2022-2032.

The market’s direction indicates a profound influence on pharmaceutical care. Companies that skillfully navigate regulatory challenges and embrace technological advancements are positioned for substantial success in this transformative landscape.

Market Analysis: Trends, Data, and Growth Projections

BIS Research, a leading market research firm, has released a report titled Biologics CDMO Market which discusses the challenges, growth factors, and future opportunities driving the remarkable market growth.

The Biologics CDMO Market report focuses on several segments such as cell type, indication, molecule type, region, etc.

China dominated the Asia-Pacific market in 2022 with a share of 40.18%. Moreover, by molecule type the market was dominated by the monoclonal antibodies segment.

Key Players and Market Shares

Having a worldwide presence, these Contract Development and Manufacturing Organizations (CDMOs) are strategically positioned to meet the growing industry demand for flexible, high-quality, and efficient solutions in the development and manufacturing of biologics.

Some major companies operating in the Biologics CDMO Market are:

AbbVie Inc.
AGC Biologics
Binex Co. Limited
Boehringer Ingelheim International GmbH
Catalent, Inc
Lonza
Novartis AG
Parexel International Corporation
Samsung Biologics
Toyobo Co., Ltd.

Market Drivers, Challenges, and Opportunities

Regulatory advancements, ongoing research, and collaboration between industry leaders are contributing factors in the growth of the Biologics CDMO Market.

Market Drivers:

Growing Biologics Approvals and Development
Rising Prevalence of Chronic Infectious Diseases
Advantages of Investment in Contract Manufacturing Facilities

Market Restraints:

Stringent Regulatory Requirements
Shortage of Skilled Professionals in Bioprocessing and Biomanufacturing

Market Opportunities:

New Outsourcing Opportunities in China
Potential for Additional CDMO and Big Pharma Alliances

Related Reports

Nucleic Acid Therapeutics CDMO Market

Analyst Note

BIS principal analyst suggests: “The global biologics CDMO market is experiencing significant growth driven by a confluence of factors. One of the primary drivers is the growing number of biologics approvals and developments, as the surge in approvals reflects the growing significance of biopharmaceuticals in treating various medical conditions and the expanding pipeline of innovative biologic drugs.”

About BIS Research

BIS Research is a global B2B market intelligence and advisory firm focusing on deep technology and related emerging trends, which can disrupt the market dynamics in the near future. We publish over 200 market intelligence studies annually, focusing on several deep technology verticals.

Our strategic market analysis emphasizes market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.

BIS Research offers syndicate and custom studies and expert consultations to firms, providing them with specific and actionable insights on novel technology markets, business models, and competitive landscapes.